These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 21725039

  • 1. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS.
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [Abstract] [Full Text] [Related]

  • 2. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [Abstract] [Full Text] [Related]

  • 3. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.
    Clin Cancer Res; 2006 Jul 01; 12(13):3908-14. PubMed ID: 16818686
    [Abstract] [Full Text] [Related]

  • 4. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M.
    Clin Cancer Res; 2011 Mar 01; 17(5):1160-8. PubMed ID: 21233402
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.
    Lung Cancer; 2012 Sep 01; 77(3):556-60. PubMed ID: 22677429
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
    Lung Cancer; 2011 Jan 01; 71(1):65-9. PubMed ID: 20430469
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov 01; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T.
    J Clin Oncol; 2005 Oct 01; 23(28):6829-37. PubMed ID: 15998907
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N.
    Oncology; 2014 Oct 01; 87(4):215-23. PubMed ID: 25034225
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC.
    Clin Cancer Res; 2011 Jun 01; 17(11):3812-21. PubMed ID: 21531810
    [Abstract] [Full Text] [Related]

  • 15. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
    Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC.
    Am J Respir Crit Care Med; 2008 Oct 15; 178(8):847-53. PubMed ID: 18583573
    [Abstract] [Full Text] [Related]

  • 16. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK.
    J Clin Oncol; 2005 Apr 10; 23(11):2493-501. PubMed ID: 15710947
    [Abstract] [Full Text] [Related]

  • 17. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
    Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.
    Cancer Cytopathol; 2013 Oct 10; 121(10):552-60. PubMed ID: 23780873
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
    Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5385-90. PubMed ID: 17875767
    [Abstract] [Full Text] [Related]

  • 19. Screening for epidermal growth factor receptor mutations in lung cancer.
    Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M, Spanish Lung Cancer Group.
    N Engl J Med; 2009 Sep 03; 361(10):958-67. PubMed ID: 19692684
    [Abstract] [Full Text] [Related]

  • 20. EGFR mutations as a predictive marker of cytotoxic chemotherapy.
    Park JH, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS.
    Lung Cancer; 2012 Aug 03; 77(2):433-7. PubMed ID: 22521649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.